---
document_datetime: 2025-12-29 08:18:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/gefitinib-mylan.html
document_name: gefitinib-mylan.html
version: success
processing_time: 0.1038485
conversion_datetime: 2025-12-30 22:17:05.631872
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Gefitinib Mylan

[RSS](/en/individual-human-medicine.xml/66910)

##### Withdrawn

This medicine's authorisation has been withdrawn

gefitinib Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Gefitinib Mylan](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 27 September 2024, the European Commission withdrew the marketing authorisation for Gefitinib Mylan (gefitinib) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Mylan Pharmaceuticals Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Gefitinib Mylan was granted marketing authorisation in the EU on 27 September 2018 for the treatment of non-small cell lung cancer. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2023. The product had not been marketed in the EU since 2023.

Gefitinib Mylan is a generic medicine of Iressa.The European Public Assessment Report (EPAR) for Gefitinib Mylan is updated to indicate that the marketing authorisation is no longer valid

Gefitinib Mylan : EPAR - Medicine overview

Reference Number: EMA/554427/20188

English (EN) (162.75 KB - PDF)

**First published:** 10/10/2018

**Last updated:** 17/10/2024

[View](/en/documents/overview/gefitinib-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-703)

български (BG) (214.02 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/bg/documents/overview/gefitinib-mylan-epar-medicine-overview_bg.pdf)

español (ES) (161.64 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/es/documents/overview/gefitinib-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (198.39 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/cs/documents/overview/gefitinib-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (158.12 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/da/documents/overview/gefitinib-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (163.02 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/de/documents/overview/gefitinib-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (151.62 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/et/documents/overview/gefitinib-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (229.27 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/el/documents/overview/gefitinib-mylan-epar-medicine-overview_el.pdf)

français (FR) (161.94 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/fr/documents/overview/gefitinib-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (182.5 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/hr/documents/overview/gefitinib-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (156.86 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/it/documents/overview/gefitinib-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (190.93 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/lv/documents/overview/gefitinib-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (189.96 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/lt/documents/overview/gefitinib-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (189.12 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/hu/documents/overview/gefitinib-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (199.31 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/mt/documents/overview/gefitinib-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (163.68 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/nl/documents/overview/gefitinib-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (192.42 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/pl/documents/overview/gefitinib-mylan-epar-medicine-overview_pl.pdf)

português (PT) (159.94 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/pt/documents/overview/gefitinib-mylan-epar-medicine-overview_pt.pdf)

română (RO) (197.65 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/ro/documents/overview/gefitinib-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (189.32 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/sk/documents/overview/gefitinib-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (182.65 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/sl/documents/overview/gefitinib-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (155.48 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/fi/documents/overview/gefitinib-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (156.8 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/sv/documents/overview/gefitinib-mylan-epar-medicine-overview_sv.pdf)

Gefitinib Mylan : EPAR - Risk-management-plan summary

English (EN) (197.74 KB - PDF)

**First published:** 10/10/2018

**Last updated:** 17/10/2024

[View](/en/documents/rmp-summary/gefitinib-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Gefitinib Mylan : EPAR - Product Information

English (EN) (1.38 MB - PDF)

**First published:** 10/10/2018

**Last updated:** 17/10/2024

[View](/en/documents/product-information/gefitinib-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-138)

български (BG) (1.92 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/bg/documents/product-information/gefitinib-mylan-epar-product-information_bg.pdf)

español (ES) (1.46 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/es/documents/product-information/gefitinib-mylan-epar-product-information_es.pdf)

čeština (CS) (1.9 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/cs/documents/product-information/gefitinib-mylan-epar-product-information_cs.pdf)

dansk (DA) (1.56 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/da/documents/product-information/gefitinib-mylan-epar-product-information_da.pdf)

Deutsch (DE) (1.73 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/de/documents/product-information/gefitinib-mylan-epar-product-information_de.pdf)

eesti keel (ET) (2.06 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/et/documents/product-information/gefitinib-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (859.75 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/el/documents/product-information/gefitinib-mylan-epar-product-information_el.pdf)

français (FR) (1.54 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/fr/documents/product-information/gefitinib-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (1.58 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/hr/documents/product-information/gefitinib-mylan-epar-product-information_hr.pdf)

íslenska (IS) (1.39 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/is/documents/product-information/gefitinib-mylan-epar-product-information_is.pdf)

italiano (IT) (1.84 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/it/documents/product-information/gefitinib-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (2.07 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/lv/documents/product-information/gefitinib-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.03 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/lt/documents/product-information/gefitinib-mylan-epar-product-information_lt.pdf)

magyar (HU) (984.8 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/hu/documents/product-information/gefitinib-mylan-epar-product-information_hu.pdf)

Malti (MT) (2 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/mt/documents/product-information/gefitinib-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (1.44 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/nl/documents/product-information/gefitinib-mylan-epar-product-information_nl.pdf)

norsk (NO) (1.44 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/no/documents/product-information/gefitinib-mylan-epar-product-information_no.pdf)

polski (PL) (1.61 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/pl/documents/product-information/gefitinib-mylan-epar-product-information_pl.pdf)

português (PT) (1.35 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/pt/documents/product-information/gefitinib-mylan-epar-product-information_pt.pdf)

română (RO) (1.66 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/ro/documents/product-information/gefitinib-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (811.04 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/sk/documents/product-information/gefitinib-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (756.13 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/sl/documents/product-information/gefitinib-mylan-epar-product-information_sl.pdf)

Suomi (FI) (717.19 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/fi/documents/product-information/gefitinib-mylan-epar-product-information_fi.pdf)

svenska (SV) (1.47 MB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/sv/documents/product-information/gefitinib-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0008 23/06/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Gefitinib Mylan : EPAR - All Authorised presentations

English (EN) (36.56 KB - PDF)

**First published:** 10/10/2018

**Last updated:** 17/10/2024

[View](/en/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-286)

български (BG) (74.74 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/bg/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (38.71 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/es/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (50.69 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/cs/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (36.62 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/da/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (32.2 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/de/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (37.78 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/et/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (78.94 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/el/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (37 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/fr/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (67.13 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/hr/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (36.41 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/is/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (37.44 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/it/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (68.47 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/lv/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (69.91 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/lt/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (69.03 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/hu/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (68.77 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/mt/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (36.73 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/nl/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (36.15 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/no/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (51.96 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/pl/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (37.72 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/pt/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (67.32 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/ro/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.15 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/sk/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (50.89 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/sl/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (36.75 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/fi/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (36.67 KB - PDF)

**First published:**

10/10/2018

**Last updated:**

17/10/2024

[View](/sv/documents/all-authorised-presentations/gefitinib-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Gefitinib Mylan Active substance gefitinib International non-proprietary name (INN) or common name gefitinib Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01XE02

### Pharmacotherapeutic group

- Antineoplastic agents
- Protein kinase inhibitors

### Therapeutic indication

Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with activating mutations of EGFR TK.

## Authorisation details

EMA product number EMEA/H/C/004826

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Pharmaceuticals Limited

Damastown Industrial Park

Opinion adopted 26/07/2018 Marketing authorisation issued 27/09/2018 Withdrawal of marketing authorisation 27/09/2024 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Gefitinib Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (248.27 KB - PDF)

**First published:** 21/06/2019

**Last updated:** 17/10/2024

[View](/en/documents/procedural-steps-after/gefitinib-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Gefitinib Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/587444/2018

English (EN) (1.28 MB - PDF)

**First published:** 10/10/2018

**Last updated:** 17/10/2024

[View](/en/documents/assessment-report/gefitinib-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Gefitinib Mylan

Adopted

Reference Number: EMA/489607/2018

English (EN) (118.06 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 17/10/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-gefitinib-mylan_en.pdf)

#### News on Gefitinib Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

**This page was last updated on** 17/10/2024

## Share this page

[Back to top](#main-content)